Oligodendroglioma history and symptoms: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
When evaluating a [[patient]] for [[oligodendroglioma]], a [[Detailed balance|detailed]] [[History and Physical examination|history]] of the [[presenting symptom]] (onset, duration, and progression), other [[Association (statistics)|associated]] [[symptoms]], a thorough past [[medical history]][[review]], and [[review]] of common [[risk factors]] such as [[family history]] of [[brain tumors]]. [[Oligodendroglioma]] is a [[slow]]-[[Growth|growing]], [[Infiltration (medical)|infiltrative]] [[tumor]] that may be [[Clinical|clinically]] silent for many [[Year|years]]. With [[tumor]]<nowiki/>progression, [[symptoms]] may vary depending upon the [[Location parameter|location]], [[Size consistency|size]], and [[rate]] of [[tumor]] [[growth]]. [[Oligodendroglioma]] mainly involves the [[frontal lobe]]. [[Symptoms]] [[Association (statistics)|associated]] with [[oligodendroglioma]] | When evaluating a [[patient]] for [[oligodendroglioma]], a [[Detailed balance|detailed]] [[History and Physical examination|history]] of the [[presenting symptom]] (onset, duration, and progression), other [[Association (statistics)|associated]] [[symptoms]], a thorough past [[medical history]][[review]], and [[review]] of common [[risk factors]] such as [[family history]] of [[brain tumors]]. [[Oligodendroglioma]] is a [[slow]]-[[Growth|growing]], [[Infiltration (medical)|infiltrative]] [[tumor]] that may be [[Clinical|clinically]] silent for many [[Year|years]]. With [[tumor]]<nowiki/>progression, [[symptoms]] may vary depending upon the [[Location parameter|location]], [[Size consistency|size]], and [[rate]] of [[tumor]] [[growth]]. [[Oligodendroglioma]] mainly involves the [[frontal lobe]]. [[Symptoms]] [[Association (statistics)|associated]] with [[oligodendroglioma]] include [[seizure]], [[headache]], [[nausea]], [[vomiting]], [[vertigo]], [[visual loss]], [[diplopia]], [[strabismus]], [[Hemiparesis|muscle weakness]], [[numbness]], [[speech difficulties]], [[mood disturbances]], [[personality changes]], [[memory]] [[Problem Solved|problems]], low [[energy]], [[fatigue]], [[Urgency|urge]] to [[sleep]], [[Loss function|loss]] of [[Interest (emotion)|interest]] in [[Activities of daily living|daily activities]], [[abulia]], [[Lack (manque)|lack]] of spontaneity, [[loss of consciousness]] with [[syncope]] (few [[tonic-clonic]] [[Jerking|jerks]]), and classic [[Triad (anatomy)|triad]] of [[headache]], [[nausea]], and [[papilledema]] due to [[raised intracranial pressure]]. | ||
==History== | ==History== | ||
| Line 18: | Line 19: | ||
==Symptoms== | ==Symptoms== | ||
* Oligodendroglioma is a slow-growing, infiltrative tumor that may be clinically silent for many years | * [[Oligodendroglioma]] is a slow-growing, [[Infiltration (medical)|infiltrative]] [[tumor]] that may be [[Clinical|clinically]] silent for many [[Year|years]] | ||
* Asymptomatic patients are diagnosed based on incidental findings at the time of brain imaging performed for another reason ( | * [[Asymptomatic]] [[patients]] are [[Diagnose|diagnosed]] based on [[Incidental finding|incidental findings]] at the [[Time series|time]] of [[brain imaging]] [[Performance status|performed]] for another [[Reasoning|reason]] (e.g: [[trauma]], [[migraine headaches]]) | ||
* Focal neurologic deficits and generalized symptoms such as headache are uncommon at the time of diagnosis | * Focal [[Neurological|neurologic]] deficits and generalized [[symptoms]] such as [[headache]] are uncommon at the [[Time series|time]] of [[diagnosis]] | ||
* With tumor progression, symptoms may vary depending on following characteristics of tumor: | * With [[tumor]] progression, [[symptoms]] may vary [[Dependent variable|depending]] on following characteristics of [[tumor]]: | ||
** Location | ** [[Location parameter|Location]] | ||
** Size | ** [[Size consistency|Size]] | ||
** Rate of tumor growth | ** [[Rate]] of [[tumor]] [[growth]] | ||
* It mainly involves the '''frontal lobe''' | * It mainly involves the '''[[frontal lobe]]''' | ||
* Common symptoms associated with oligodendroglioma include:<ref name="pmid9684012">{{cite journal| author=Douay X, Daems-Monpeurt C, Labalette P, Blond S, Petit H| title=[Bilateral 3rd cranial nerve palsy disclosing oligodendroglioma]. | journal=Rev Neurol (Paris) | year= 1997 | volume= 153 | issue= 6-7 | pages= 430-2 | pmid=9684012 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9684012 }} </ref><ref name="pmid17553214">{{cite journal| author=Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S et al.| title=Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. | journal=Neurol Res | year= 2007 | volume= 29 | issue= 7 | pages= 723-6 | pmid=17553214 | doi=10.1179/016164107X208068 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17553214 }} </ref><ref name="pmid1695334">{{cite journal| author=Ogasawara H, Kiya K, Uozumi T, Sugiyama K, Kawamoto K, Ohta M| title=Multiple oligodendroglioma--case report. | journal=Neurol Med Chir (Tokyo) | year= 1990 | volume= 30 | issue= 2 | pages= 127-31 | pmid=1695334 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1695334 }} </ref><ref name="pmid2308753">{{cite journal| author=Raciti-Daurio C, Caruso J| title=Oligodendroglioma--a case presentation. | journal=Optom Vis Sci | year= 1990 | volume= 67 | issue= 1 | pages= 56-8 | pmid=2308753 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2308753 }} </ref><ref name="pmid24805856">{{cite journal| author=Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B et al.| title=Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. | journal=Am J Surg Pathol | year= 2014 | volume= 38 | issue= 8 | pages= 1058-70 | pmid=24805856 | doi=10.1097/PAS.0000000000000221 | pmc=4322928 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24805856 }} </ref> | * Common [[symptoms]] [[Association (statistics)|associated]] with [[oligodendroglioma]] include:<ref name="pmid9684012">{{cite journal| author=Douay X, Daems-Monpeurt C, Labalette P, Blond S, Petit H| title=[Bilateral 3rd cranial nerve palsy disclosing oligodendroglioma]. | journal=Rev Neurol (Paris) | year= 1997 | volume= 153 | issue= 6-7 | pages= 430-2 | pmid=9684012 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9684012 }} </ref><ref name="pmid17553214">{{cite journal| author=Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S et al.| title=Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. | journal=Neurol Res | year= 2007 | volume= 29 | issue= 7 | pages= 723-6 | pmid=17553214 | doi=10.1179/016164107X208068 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17553214 }} </ref><ref name="pmid1695334">{{cite journal| author=Ogasawara H, Kiya K, Uozumi T, Sugiyama K, Kawamoto K, Ohta M| title=Multiple oligodendroglioma--case report. | journal=Neurol Med Chir (Tokyo) | year= 1990 | volume= 30 | issue= 2 | pages= 127-31 | pmid=1695334 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1695334 }} </ref><ref name="pmid2308753">{{cite journal| author=Raciti-Daurio C, Caruso J| title=Oligodendroglioma--a case presentation. | journal=Optom Vis Sci | year= 1990 | volume= 67 | issue= 1 | pages= 56-8 | pmid=2308753 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2308753 }} </ref><ref name="pmid24805856">{{cite journal| author=Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B et al.| title=Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. | journal=Am J Surg Pathol | year= 2014 | volume= 38 | issue= 8 | pages= 1058-70 | pmid=24805856 | doi=10.1097/PAS.0000000000000221 | pmc=4322928 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24805856 }} </ref> | ||
**[[Seizure]] (usually the first and most common presentation in 50-80% of the cases)<ref name="pmid17172614">{{cite journal| author=Cavaliere R, Farace E, Schiff D| title=Clinical implications of status epilepticus in patients with neoplasms. | journal=Arch Neurol | year= 2006 | volume= 63 | issue= 12 | pages= 1746-9 | pmid=17172614 | doi=10.1001/archneur.63.12.1746 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17172614 }} </ref> | **[[Seizure]] (usually the first and most common [[Presentation (Obstetrics)|presentation]] in 50-80% of the cases)<ref name="pmid17172614">{{cite journal| author=Cavaliere R, Farace E, Schiff D| title=Clinical implications of status epilepticus in patients with neoplasms. | journal=Arch Neurol | year= 2006 | volume= 63 | issue= 12 | pages= 1746-9 | pmid=17172614 | doi=10.1001/archneur.63.12.1746 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17172614 }} </ref> | ||
**[[Headache]] | **[[Headache]] | ||
**[[Nausea]] | **[[Nausea]] | ||
**[[Vomiting]] | **[[Vomiting]] | ||
**[[Vertigo]] | **[[Vertigo]] | ||
**'''Focal neurological deficits''' depending upon tumor location (symptoms usually caused by local tissue disruption, mass effect on nearby structures, or vasogenic edema) include: | **'''Focal [[neurological]] deficits''' depending upon [[tumor]] [[Location parameter|location]] ([[symptoms]] usually [[Causes|caused]] by [[local]] [[Tissue (biology)|tissue]] [[Disruption (of schema)|disruption]], [[Mass effect (medicine)|mass effect]] on nearby [[Structure factor|structures]], or [[vasogenic edema]]) include: | ||
***[[hemiparesis|Muscle weakness]] | ***[[hemiparesis|Muscle weakness]] | ||
***[[Numbness]]/sensory loss | ***[[Numbness]]/[[sensory loss]] | ||
***[[Dysarthria|Changes in speech]]/aphasia | ***[[Dysarthria|Changes in speech]]/[[aphasia]] | ||
***[[Visual loss]]/visual spatial dysfunction | ***[[Visual loss]]/[[visual]] [[Spatial analysis|spatial]] [[dysfunction]] | ||
***[[Diplopia]] | ***[[Diplopia]] | ||
***[[Strabismus]] | ***[[Strabismus]] | ||
**'''Cognitive dysfunction''' includes: | **'''[[Cognitive]] [[dysfunction]]''' includes: | ||
***Memory problems | ***[[Memory]] [[Problem Solved|problems]] | ||
***[[mood disorders|Changes in mood]] | ***[[mood disorders|Changes in mood]] | ||
***[[personality pathology|Changes in personality]] | ***[[personality pathology|Changes in personality]] | ||
***Low energy | ***Low [[energy]] | ||
***Fatigue | ***[[Fatigue]] | ||
***Urge to sleep | ***[[Urgency|Urge]] to [[sleep]] | ||
***Loss of interest in daily activities | ***[[Loss function|Loss]] of [[Interest (emotion)|interest]] in [[Activities of daily living|daily activities]] | ||
***Abulia (showing abnormal inability to act or make decisions) | ***Abulia (showing abnormal inability to act or make decisions) | ||
***Lack of spontaneity | ***Lack of spontaneity | ||
Revision as of 22:14, 18 May 2019
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma history and symptoms On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma history and symptoms |
|
Risk calculators and risk factors for Oligodendroglioma history and symptoms |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
When evaluating a patient for oligodendroglioma, a detailed history of the presenting symptom (onset, duration, and progression), other associated symptoms, a thorough past medical historyreview, and review of common risk factors such as family history of brain tumors. Oligodendroglioma is a slow-growing, infiltrative tumor that may be clinically silent for many years. With tumorprogression, symptoms may vary depending upon the location, size, and rate of tumor growth. Oligodendroglioma mainly involves the frontal lobe. Symptoms associated with oligodendroglioma include seizure, headache, nausea, vomiting, vertigo, visual loss, diplopia, strabismus, muscle weakness, numbness, speech difficulties, mood disturbances, personality changes, memory problems, low energy, fatigue, urge to sleep, loss of interest in daily activities, abulia, lack of spontaneity, loss of consciousness with syncope (few tonic-clonic jerks), and classic triad of headache, nausea, and papilledema due to raised intracranial pressure.
History
- While evaluating a patient for oligodendroglioma, a detailed history of the following should be taken:[1]
- Presenting symptom:
- Onset
- Duration
- Progression
- Other associated symptoms
- A thorough past medical history review
- Review of common risk factors such as:
- Presenting symptom:
Symptoms
- Oligodendroglioma is a slow-growing, infiltrative tumor that may be clinically silent for many years
- Asymptomatic patients are diagnosed based on incidental findings at the time of brain imaging performed for another reason (e.g: trauma, migraine headaches)
- Focal neurologic deficits and generalized symptoms such as headache are uncommon at the time of diagnosis
- With tumor progression, symptoms may vary depending on following characteristics of tumor:
- It mainly involves the frontal lobe
- Common symptoms associated with oligodendroglioma include:[2][3][4][5][6]
- Seizure (usually the first and most common presentation in 50-80% of the cases)[7]
- Headache
- Nausea
- Vomiting
- Vertigo
- Focal neurological deficits depending upon tumor location (symptoms usually caused by local tissue disruption, mass effect on nearby structures, or vasogenic edema) include:
- Cognitive dysfunction includes:
- Memory problems
- Changes in mood
- Changes in personality
- Low energy
- Fatigue
- Urge to sleep
- Loss of interest in daily activities
- Abulia (showing abnormal inability to act or make decisions)
- Lack of spontaneity
- Increased intracranial pressure (either due to a large mass or any restriction in cerebrospinal fluid outflow causing hydrocephalus) associated with following symptoms:
- Classic triad that includes:
- Headache
- Nausea
- Papilledema
- Loss of consciousness with syncope (maybe associated with a few tonic-clonic jerks)
- Classic triad that includes:
| Tumor site of involvement | Clinical features |
|---|---|
| Frontal lobe |
|
| Temporal lobe |
|
References
- ↑ McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H; et al. (2011). "Risk factors for oligodendroglial tumors: a pooled international study". Neuro Oncol. 13 (2): 242–50. doi:10.1093/neuonc/noq173. PMC 3064625. PMID 21149253.
- ↑ Douay X, Daems-Monpeurt C, Labalette P, Blond S, Petit H (1997). "[Bilateral 3rd cranial nerve palsy disclosing oligodendroglioma]". Rev Neurol (Paris). 153 (6–7): 430–2. PMID 9684012.
- ↑ Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S; et al. (2007). "Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy". Neurol Res. 29 (7): 723–6. doi:10.1179/016164107X208068. PMID 17553214.
- ↑ Ogasawara H, Kiya K, Uozumi T, Sugiyama K, Kawamoto K, Ohta M (1990). "Multiple oligodendroglioma--case report". Neurol Med Chir (Tokyo). 30 (2): 127–31. PMID 1695334.
- ↑ Raciti-Daurio C, Caruso J (1990). "Oligodendroglioma--a case presentation". Optom Vis Sci. 67 (1): 56–8. PMID 2308753.
- ↑ Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B; et al. (2014). "Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients". Am J Surg Pathol. 38 (8): 1058–70. doi:10.1097/PAS.0000000000000221. PMC 4322928. PMID 24805856.
- ↑ Cavaliere R, Farace E, Schiff D (2006). "Clinical implications of status epilepticus in patients with neoplasms". Arch Neurol. 63 (12): 1746–9. doi:10.1001/archneur.63.12.1746. PMID 17172614.